CIK: 0001839435
Total reported value
$903.6M
Reporting period: 2026-03-31 · Number of holdings: 29
Octagon Capital Advisors LP disclosed 29 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $903.6M and a quarterly turnover rate of 68.3%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "O"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add DNTH
-19.4% $63.8M
Trim GOSS
-44.3% -$40.6M
Trim ABVX
-10.4% -$26.6M
Add ALMS
+11.9% $37.7M
Trim TRVI
-47.2% -$17.5M
Trim PHVS
-75.4% -$14.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | Stock-Other | 18.08% | +5.99% | -19.45% | |
| 2 | COGT | Cogent Biosciences INC | Stock-Other | 10.01% | -0.12% | — | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 8.34% | -4.04% | -10.45% | |
| 4 | ALMS | Alumis INC | Stock-Other | 6.90% | +3.90% | +11.85% | |
| 5 | DFTX | Definium Therapeutics INC | Stock-Other | 5.10% | +5.10% | NEW | |
| 6 | AVBP | Arrivent Biopharma INC | Stock-Other | 5.03% | +0.22% | — | |
| 7 | TSHA | Taysha Gene Therapies INC | Stock-Other | 4.38% | -1.54% | — | |
| 8 | KYMR | Kymera Therapeutics INC | Stock-Other | 3.92% | -1.13% | -20.56% | |
| 9 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 3.46% | +3.46% | NEW | |
| 10 | BIOA | Bioage Labs INC | Stock-Other | 3.38% | +0.81% | +9.39% | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.30% | +1.02% | — | |
| 12 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 3.23% | +0.73% | +13.87% | |
| 13 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 3.15% | +3.15% | NEW | |
| 14 | 430 | Terns Pharmaceuticals INC | Stock-Other | 3.09% | +3.09% | NEW | |
| 15 | OCUL | Ocular Therapeutix INC | Stock-Other | 2.97% | -0.90% | +20.70% | |
| 16 | PALI | Palisade Bio INC | Stock-Other | 1.99% | -0.74% | +7.40% | |
| 17 | TRVI | Trevi Therapeutics INC | Stock-Other | 1.96% | -2.32% | -47.25% | |
| 18 | IRON | Disc Medicine INC | Stock-Other | 1.91% | +1.91% | NEW | |
| 19 | AKTS | Aktis Oncology INC | Stock-Other | 1.90% | +1.90% | NEW | |
| 20 | CNTX | Context Therapeutics INC | Stock-Other | 1.52% | +1.52% | NEW | |
| 21 | DTIL | Precision Biosciences INC | Stock-Other | 1.36% | +0.39% | +16.62% | |
| 22 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.33% | -0.01% | — | |
| 23 | UNCY | Unicycive Therapeutics INC | Stock-Other | 0.73% | +0.03% | — | |
| 24 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.71% | -0.88% | -31.07% | |
| 25 | LXEO | Lexeo Therapeutics INC | Stock-Other | 0.70% | -1.38% | -36.23% | |
| 26 | PHVS | Pharvaris N.V. | Stock-Other | 0.52% | -1.74% | -75.43% | |
| 27 | CATX | Perspective Therapeutics INC | Stock-Other | 0.37% | +0.37% | NEW | |
| 28 | EVMN | Evommune INC | Stock-Other | 0.37% | -0.68% | -71.31% | |
| 29 | GOSS | Gossamer Bio INC | Stock-Other | 0.28% | -4.96% | -44.31% |
Performance for Q3 2026
+18.3%
Performance Last 4 Quarters
+114.7%
Based on 80% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 29 | $903.6M | 68 | |
| 2025-12-31 | 27 | $823.7M | 49 | |
| 2025-09-30 | 27 | $659.8M | 100 | |
| 2025-06-30 | 30 | $455.6M | 0 | |
| 2025-03-31 | 35 | $516.8M | 100 | |
| 2024-12-31 | 33 | $607.7M | 0 | |
| 2024-09-30 | 42 | $642.9M | 0 | |
| 2024-06-30 | 47 | $636.3M | 0 | |
| 2024-03-31 | 57 | $834.4M | 0 | |
| 2023-12-31 | 33 | $625.0M | 0 | |
| 2023-09-30 | 40 | $650.9M | 0 | |
| 2023-06-30 | 41 | $718.7M | 0 | |
| 2023-03-31 | 36 | $695.0M | 0 | |
| 2022-12-31 | 32 | $642.2M | 0 | |
| 2022-09-30 | 35 | $579.4M | 0 | |
| 2022-06-30 | 20 | $374.7M | 0 | |
| 2022-03-31 | 24 | $462.6M | 0 | |
| 2021-12-31 | 28 | $513.9M | 0 | |
| 2021-09-30 | 30 | $406.1M | 0 | |
| 2021-06-30 | 34 | $482.8M | 72 | |
| 2021-03-31 | 28 | $265.5M | 50 | |
| 2020-12-31 | 31 | $288.5M | 0 |
Octagon Capital Advisors LP's most significant position changes for 2026-03-31: New buy: Definium Therapeutics INC (DFTX); New buy: Mirum Pharmaceuticals INC (MIRM); Sold out: Mind Medicine Mindmed INC (BRD1EUR); New buy: Xenon Pharmaceuticals INC (XENE); New buy: Terns Pharmaceuticals INC (430).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | +6% | -19.45% | Trim |
| 2 | ALMS | Alumis INC | +3.9% | +11.85% | Add |
| 3 | 260 | Centessa Pharmaceuticals-adr | +1% | — | Unchanged |
| 4 | BIOA | Bioage Labs INC | +0.8% | +9.39% | Add |
| 5 | 4XC1 | Kalvista Pharmaceuticals INC | +0.7% | +13.87% | Add |
| 6 | DTIL | Precision Biosciences INC | +0.4% | +16.62% | Add |
| 7 | AVBP | Arrivent Biopharma INC | +0.2% | — | Unchanged |
| 8 | UNCY | Unicycive Therapeutics INC | 0% | — | Unchanged |
| 9 | DBVT | Dbv Technologies Sa-spon Adr | 0% | — | Unchanged |
| 10 | COGT | Cogent Biosciences INC | -0.1% | — | Unchanged |
| 11 | EVMN | Evommune INC | -0.7% | -71.31% | Trim |
| 12 | PALI | Palisade Bio INC | -0.7% | +7.40% | Add |
| 13 | BBOT | Bridgebio Oncology Therapeut | -0.9% | -31.07% | Trim |
| 14 | OCUL | Ocular Therapeutix INC | -0.9% | +20.70% | Add |
| 15 | KYMR | Kymera Therapeutics INC | -1.1% | -20.56% | Trim |
| 16 | LXEO | Lexeo Therapeutics INC | -1.4% | -36.23% | Trim |
| 17 | TSHA | Taysha Gene Therapies INC | -1.5% | — | Unchanged |
| 18 | PHVS | Pharvaris N.V. | -1.7% | -75.43% | Trim |
| 19 | TRVI | Trevi Therapeutics INC | -2.3% | -47.25% | Trim |
| 20 | ABVX | Abivax Sa-adr | -4% | -10.45% | Trim |
| 21 | GOSS | Gossamer Bio INC | -5% | -44.31% | Trim |
| 22 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 23 | MIRM | Mirum Pharmaceuticals INC | — | NEW | New buy |
| 24 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 25 | XENE | Xenon Pharmaceuticals INC | — | NEW | New buy |
| 26 | 430 | Terns Pharmaceuticals INC | — | NEW | New buy |
| 27 | CGON | Cg Oncology INC | — | EXIT | Sold out |
| 28 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| 29 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 30 | IRON | Disc Medicine INC | — | NEW | New buy |
| 31 | AKTS | Aktis Oncology INC | — | NEW | New buy |
| 32 | CNTX | Context Therapeutics INC | — | NEW | New buy |
| 33 | CRBP | Corbus Pharmaceuticals Holdi | — | EXIT | Sold out |
| 34 | PEPG | Pepgen INC | — | EXIT | Sold out |
| 35 | CATX | Perspective Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-16 | Amendment | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001728121
Total reported value
$903.4M
550 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0001535264
Total reported value
$903.4M
98 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002110759
Total reported value
$903.8M
336 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001335325
Total reported value
$362.2M
156 stks
2026-03-31
2 of the top 5 holdings overlap, including Abivax Sa-adr
CIK 0001802528
Total reported value
$1.4B
12 stks
2026-03-31
2 of the top 5 holdings overlap, including Dianthus Therapeutics INC
CIK 0001816307
Total reported value
$979.8M
73 stks
2026-03-31
2 of the top 5 holdings overlap, including Dianthus Therapeutics INC